Larimar Therapeutics Inc (LRMR)
7.43
-0.44
(-5.59%)
USD |
NASDAQ |
May 16, 16:00
7.43
0.00 (0.00%)
After-Hours: 20:00
Larimar Therapeutics Net Income (Quarterly): -14.65M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -14.65M |
| December 31, 2023 | -12.99M |
| September 30, 2023 | -9.064M |
| June 30, 2023 | -8.366M |
| March 31, 2023 | -6.526M |
| December 31, 2022 | -9.425M |
| September 30, 2022 | -8.32M |
| June 30, 2022 | -8.667M |
| March 31, 2022 | -8.943M |
| December 31, 2021 | -9.134M |
| Date | Value |
|---|---|
| September 30, 2021 | -16.80M |
| June 30, 2021 | -12.61M |
| March 31, 2021 | -12.09M |
| December 31, 2020 | -14.20M |
| September 30, 2020 | -10.27M |
| June 30, 2020 | -11.33M |
| March 31, 2020 | -6.674M |
| December 31, 2019 | -6.076M |
| September 30, 2019 | -8.628M |
| June 30, 2019 | -3.704M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-16.80M
Minimum
Sep 2021
-3.704M
Maximum
Jun 2019
-9.924M
Average
-9.099M
Median
Net Income (Quarterly) Benchmarks
| Cogent Biosciences Inc | -58.35M |
| ACADIA Pharmaceuticals Inc | 16.56M |
| PTC Therapeutics Inc | -91.58M |
| Renovaro Inc | -4.529M |
| G1 Therapeutics Inc | -10.22M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 16.73M |
| EPS Diluted (Quarterly) | -0.27 |
| Enterprise Value | 246.75M |
| Earnings Yield | -12.92% |